Empliciti and Gastrointestinal disorder - a phase IV clinical study of FDA data

Summary:

Gastrointestinal disorder is reported as a side effect among people who take Empliciti (elotuzumab), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Revlimid, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Gastrointestinal disorder when taking Empliciti. It is created by eHealthMe based on reports of 2,543 people who have side effects when taking Empliciti from the FDA, and is updated regularly.

What is Empliciti?

Empliciti has active ingredients of elotuzumab. eHealthMe is studying from 2,545 Empliciti users. Check the latest studies of Empliciti.

What is Gastrointestinal disorder?

Gastrointestinal disorder (functional problems of gastrointestinal tract) is found to be associated with 2,093 drugs and 1,908 conditions by eHealthMe. Check the latest studies of Gastrointestinal disorder.

On Jul, 13, 2026

2,543 people reported to have side effects when taking Empliciti.
Among them, 11 people (0.43%) have Gastrointestinal disorder.

Could Empliciti cause Gastrointestinal disorder?

Among these 11 people:

How long have people been on Empliciti when they have Gastrointestinal disorder? *

What is the gender of people who have Gastrointestinal disorder when taking Empliciti? *

female: 36.36 %
male: 63.64 %

What is the age of people who have Gastrointestinal disorder when taking Empliciti? *

What are other drugs people take besides Empliciti? *

What are other side effects people have besides Gastrointestinal disorder? *

Septic Shock (shock due to blood infection): 3 people, 27.27%
Nausea And Vomiting: 3 people, 27.27%
Nausea (feeling of having an urge to vomit): 3 people, 27.27%
Fatigue (feeling of tiredness): 3 people, 27.27%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 27.27%
Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract): 3 people, 27.27%
Diarrhea: 3 people, 27.27%
Constipation: 2 people, 18.18%
Rectal Perforation (tear or hole in rectum): 2 people, 18.18%
Postoperative Abscess: 2 people, 18.18%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 9 people, 81.82%
White Blood Cell Count Decreased: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Empliciti and have Gastrointestinal disorder?

- Check whether Gastrointestinal disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Empliciti:

Empliciti (2,545 reports)

Browse all side effects of Empliciti:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal disorder:

Gastrointestinal disorder (2,094 drugs)

Browse all the conditions that are associated with Gastrointestinal disorder:

Gastrointestinal disorder (1,908 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on elotuzumab (the active ingredients of Empliciti) and Empliciti (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.